Challenges in Colorectal Cancer [Hardcover]

John H. Scholefield (Editor)

Book Description

Publication Date: April 15, 2000 | ISBN-10: 0632051167 | ISBN-13: 978-0632051168 | Edition: 1

Colorectal cancers are among the most common tumor types in the western world. In over 50% of cases the tumor spreads, and in most of these the survival time is 6-12 months. The medical management of colorectal cancer has revolved around the use of one drug. Fluorouracil, introduced 30 years ago, extends life by about 10 months. Therefore, there is a desperate need to diagnose this cancer early and to develop new strategies for management.

This book focuses on the areas of controversy in the management of colorectal cancer. It reviews the latest information on:

• epidemiology and prevention of colorectal cancer, including the application of molecular genetics, and the latest strategies for screening


• surgical management, including new laparoscopic and endoscopic techniques, and the role of the pathologist


• oncological management, including the role of radiotherapy, options for chemotherapy and new developments in vaccine and immunotherapy

This book provides essential information for the gastrointenstinal surgeon, gastroenterologist and oncologist.

Editorial Reviews

From The New England Journal of Medicine

Colorectal cancer presents some of the most challenging problems for basic scientists, clinical investigators, and practitioners. It will be important to facilitate an ongoing exchange among these three groups if we are to transform many small steps into a major advance in the treatment of colorectal cancer. Surgery remains the center of attention, for two reasons. First, in any high-risk case, the surgeon must coordinate the various treatment options (e.g., preoperative, intraoperative, and postoperative adjuvant treatment); second, the surgeon determines the prognosis, since inadequate surgical technique can influence a patient's outcome more than can the stage of the disease. But there are new trends, such as risk-adjusted screening, brought about by molecular techniques that have deepened our understanding of the pathogenesis of colorectal cancer. The demonstration of micrometastases in stage II and III cancers has sharpened the need for effective adjuvant therapy.

This book deals with these challenges and presents important new developments. A consensus has evolved with respect to diagnostic and therapeutic strategies in dominantly inherited colorectal cancers (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer); by contrast, the rules for the early diagnosis of and screening for sporadic cancer remain undefined. Screening of the general population is effective but costly.

It is increasingly evident that preoperative chemotherapy or the combination of radiation therapy and chemotherapy can improve results in the treatment of rectal cancer. Experience during the past 15 years has clearly demonstrated the value of chemotherapy in high-risk colorectal cancer. It will become necessary to change the usual postoperative treatment with radiation or a combination of radiation therapy and chemotherapy to a preoperative combination, perhaps with additional intraoperative irradiation followed by postoperative chemotherapy. It is still debatable whether the excellent results of total mesorectal excision in patients with rectal cancer eliminates the need for preoperative, intraoperative, or postoperative radiation therapy. Tumor that has spread to the lymph nodes along the mesenteric border can easily be removed surgically, but removal of tumor that has spread to the pelvic wall is not part of the standard surgical procedure. Extended surgical procedures lead to high rates of irreversible loss of bladder control and impaired sexual function.

A number of new chemotherapeutic agents (oxaliplatin, irinotecan, and topotecan) and several types of immunotherapy are promising and may have clinical applications, but only if minimal residual disease can be diagnosed reliably. Dormant tumor cells are a reality and can be treated with the monoclonal antibody 17-1A. In the end, however, the solution will probably be a combination of immunotherapy and chemotherapy.

More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk-oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield's book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases.

Christian Herfarth, M.D.
Copyright © 2000 Massachusetts Medical Society. All rights reserved. The New England Journal of Medicine is a registered trademark of the MMS.

Review

"More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk- oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield’s book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases." (New England Journal of Medicine, September 2000)

See all Editorial Reviews

Product Details

• Hardcover: 230 pages
• Publisher: Wiley-Blackwell; 1 edition (April 15, 2000)
• Language: English
• ISBN-10: 0632051167
• ISBN-13: 978-0632051168
• Product Dimensions: 9.2 x 6.3 x 0.7 inches
• Shipping Weight: 1.4 pounds
• Amazon Best Sellers Rank: #6,942,755 in Books (See Top 100 in Books)